Ponatinib-induced neutrophilic panniculitis

May Zhang; Khaled M. Hassan; Amy Musiek; Ilana S. Rosman

doi:10.1111/cup.12326

Ponatinib-induced neutrophilic panniculitis

May Zhang, Khaled M. Hassan, Amy Musiek, Ilana S. Rosman

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.

Original language	English
Pages (from-to)	597-601
Number of pages	5
Journal	Journal of cutaneous pathology
Volume	41
Issue number	7
DOIs	https://doi.org/10.1111/cup.12326
State	Published - Jul 2014

Keywords

chronic myeloid leukemia
drug reaction
panniculitis
ponatinib

Access to Document

10.1111/cup.12326

Cite this

@article{08e83f4a679b4ae5ba33d7994757c753,

title = "Ponatinib-induced neutrophilic panniculitis",

abstract = "Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.",

keywords = "chronic myeloid leukemia, drug reaction, panniculitis, ponatinib",

author = "May Zhang and Hassan, {Khaled M.} and Amy Musiek and Rosman, {Ilana S.}",

year = "2014",

month = jul,

doi = "10.1111/cup.12326",

language = "English",

volume = "41",

pages = "597--601",

journal = "Journal of cutaneous pathology",

issn = "0303-6987",

number = "7",

}

TY - JOUR

T1 - Ponatinib-induced neutrophilic panniculitis

AU - Zhang, May

AU - Hassan, Khaled M.

AU - Musiek, Amy

AU - Rosman, Ilana S.

PY - 2014/7

Y1 - 2014/7

N2 - Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.

AB - Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.

KW - chronic myeloid leukemia

KW - drug reaction

KW - panniculitis

KW - ponatinib

UR - http://www.scopus.com/inward/record.url?scp=84903520834&partnerID=8YFLogxK

U2 - 10.1111/cup.12326

DO - 10.1111/cup.12326

M3 - Article

C2 - 24602068

AN - SCOPUS:84903520834

SN - 0303-6987

VL - 41

SP - 597

EP - 601

JO - Journal of cutaneous pathology

JF - Journal of cutaneous pathology

IS - 7

ER -

Ponatinib-induced neutrophilic panniculitis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this